The European Commission has granted approval for the intravenous (IV) form of sildenafil (Revatio; Pfizer), developed to be administered to patients prescribed the oral form of sildenafil who are unable to take oral medications.
The phosphodiesterase 5 (PDE5) inhibitor, sildenafil, is deployed in both oral and intravenous formulas and used in the treatment of pulmonary arterial hypertension (PAH).
The injection form of sildenafil is indicated for adult patients with PAH who are clinically and hemodynamically stable.
According to New York City-based Pfizer, sildenafil was first issued a CE Mark in October 2005 for the oral agent. Also, the use of the IV form of sildenafil was sanctioned by the FDA in November 2009.